111 Inc (YI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
111 Inc stock (YI) is currently trading at $6.29. 111 Inc PS ratio (Price-to-Sales) is 0.00. Analyst consensus price target for YI is $5.96. WallStSmart rates YI as Sell.
- YI PE ratio analysis and historical PE chart
- YI PS ratio (Price-to-Sales) history and trend
- YI intrinsic value — DCF, Graham Number, EPV models
- YI stock price prediction 2025 2026 2027 2028 2029 2030
- YI fair value vs current price
- YI insider transactions and insider buying
- Is YI undervalued or overvalued?
- 111 Inc financial analysis — revenue, earnings, cash flow
- YI Piotroski F-Score and Altman Z-Score
- YI analyst price target and Smart Rating
111 Inc
📊 No data available
Try selecting a different time range
Smart Analysis
111 Inc (YI) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
111 Inc (YI) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
111 Inc (YI) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -16.70%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 1.25%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
111 Inc (YI) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.00), Price/Book (-0.69) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -16.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -10.90%, Operating Margin at -0.08%, Profit Margin at -0.51%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -10.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -16.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
YI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
YI's Price-to-Sales ratio of 0.00x trades Infinity% above its historical average of 0x (43th percentile), historically expensive. The current valuation is 57% below its historical high of 0.01x set in Mar 2026, and Infinity% above its historical low of 0x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for 111 Inc (YI) · HEALTHCARE › MEDICAL DISTRIBUTION
The Big Picture
111 Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 13.6B with 17% decline year-over-year. The company is currently unprofitable, posting a -0.5% profit margin.
Key Findings
Generating 38M in free cash flow and 38M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of -0.30 indicates a conservative balance sheet with 464M in cash.
Revenue contracted 17% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -0.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DISTRIBUTION industry trends, competitive moves, and regulatory changes that could impact 111 Inc.
Bottom Line
111 Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:04:32 AM
About 111 Inc(YI)
NASDAQ
HEALTHCARE
MEDICAL DISTRIBUTION
China
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.